#1 Clinical Trials Search in Europe

Ofatumumab

Ofatumumab is a fully human monoclonal antibody that has shown promise in treating several conditions, including chronic lymphocytic leukemia (CLL), multiple sclerosis (MS), and other B-cell related disorders. This article explores the use of ofatumumab in various clinical trials, highlighting its potential benefits and applications across different medical conditions.

Table of Contents

What is Ofatumumab?

Ofatumumab, also known by its brand name Arzerra, is a fully human monoclonal antibody. This means it’s a type of protein made in a laboratory that can bind to specific substances in the body, including tumor cells[1]. Ofatumumab is designed to target a specific protein called CD20, which is found on the surface of certain types of immune cells called B cells[2].

How Ofatumumab Works

Ofatumumab works by attaching to the CD20 protein on B cells. This attachment triggers the body’s immune system to attack and destroy these cells. In diseases where B cells are problematic (such as certain types of cancer or autoimmune disorders), this can help control the disease[2].

Conditions Treated with Ofatumumab

Ofatumumab has been studied and used in the treatment of several conditions:

  • Chronic Lymphocytic Leukemia (CLL): This is a type of cancer that affects the blood and bone marrow. Ofatumumab has been approved for use in patients with CLL who have not responded to other treatments[3].
  • Follicular Lymphoma: This is a type of non-Hodgkin lymphoma, a cancer that starts in the lymphatic system. Ofatumumab has been studied in patients with follicular lymphoma who didn’t respond to previous treatments[2].
  • Diffuse Large B Cell Lymphoma (DLBCL): Another type of non-Hodgkin lymphoma. Ofatumumab has been studied in combination with other treatments for patients with DLBCL[4].
  • Multiple Sclerosis (MS): Ofatumumab has been approved for the treatment of relapsing forms of multiple sclerosis, a disease that affects the central nervous system[5].
  • Neuromyelitis Optica Spectrum Disorder (NMOSD): This is a rare but severe disorder that affects the optic nerves and spinal cord. Research is ongoing to determine if ofatumumab can be effective in treating this condition[5].

How Ofatumumab is Administered

Ofatumumab is typically given as an intravenous (IV) infusion, which means it’s administered directly into a vein. The dosage and frequency can vary depending on the condition being treated. For example:

  • For CLL, patients might receive weekly infusions for several weeks, followed by monthly infusions[6].
  • For multiple sclerosis, ofatumumab may be given as a subcutaneous (under the skin) injection. Patients might receive injections more frequently at the start of treatment, then move to monthly injections[5].

Efficacy of Ofatumumab

The effectiveness of ofatumumab can vary depending on the condition being treated and individual patient factors. However, clinical trials have shown promising results:

  • In CLL patients who didn’t respond to other treatments, ofatumumab has shown to improve overall survival and progression-free survival (the time during and after treatment that a patient lives with the disease without it getting worse)[3].
  • In follicular lymphoma, studies have shown that some patients who didn’t respond to other treatments had a positive response to ofatumumab[2].
  • Research in multiple sclerosis has shown that ofatumumab can reduce the number of relapses and slow the progression of disability[5].

Potential Side Effects

Like all medications, ofatumumab can cause side effects. Some of the most common include:

  • Infusion-related reactions: These can include fever, chills, rash, or difficulty breathing during or shortly after the infusion.
  • Increased risk of infections: Because ofatumumab affects the immune system, it can make patients more susceptible to infections.
  • Fatigue
  • Nausea
  • Cough

It’s important to discuss potential side effects with your healthcare provider before starting treatment[3].

Ongoing Research

Research on ofatumumab is ongoing, with several clinical trials currently in progress. These studies are looking at its effectiveness in various conditions and in combination with other treatments. For example:

  • A study is investigating the use of ofatumumab in patients with neuromyelitis optica spectrum disorder (NMOSD)[5].
  • Another study is looking at the combination of ofatumumab with other drugs in the treatment of chronic lymphocytic leukemia[7].

These ongoing studies may lead to new uses for ofatumumab or improvements in how it’s used to treat existing conditions.

Aspect Details
Drug Name Ofatumumab (also known as Arzerra or Kesimpta)
Drug Type Fully human monoclonal antibody targeting CD20
Conditions Studied Chronic lymphocytic leukemia (CLL), Multiple sclerosis (MS), Follicular lymphoma, Neuromyelitis optica spectrum disorder (NMOSD), B-cell lymphomas
Administration Methods Intravenous infusion, Subcutaneous injection
Key Outcome Measures Annualized relapse rate (ARR), Progression-free survival (PFS), Overall survival (OS), Expanded Disability Status Scale (EDSS), Response rates
Potential Benefits Reduced relapse rates, Improved response rates, Better disease control, Symptom management, Quality of life improvement
Safety Considerations Infusion-related reactions, Infections, Changes in blood cell counts

FAQ

  • What is ofatumumab and how does it work? Ofatumumab is a fully human monoclonal antibody that targets the CD20 molecule found on B cells. It works by binding to CD20 and helping to destroy B cells, which can be beneficial in treating conditions where B cells are involved in the disease process.
  • What conditions is ofatumumab being studied for in clinical trials? Ofatumumab is being studied in clinical trials for various conditions, including chronic lymphocytic leukemia (CLL), multiple sclerosis (MS), follicular lymphoma, neuromyelitis optica spectrum disorder (NMOSD), and other B-cell related disorders.
  • How is ofatumumab administered to patients? Ofatumumab can be administered in different ways depending on the condition and study. It may be given as an intravenous infusion or as a subcutaneous injection. The dosage and frequency of administration vary based on the specific trial and condition being treated.
  • What are some potential benefits of ofatumumab treatment? Potential benefits of ofatumumab treatment include reduced relapse rates in MS, improved response rates in CLL, and better control of disease progression in various B-cell related disorders. It may also help in managing symptoms and improving quality of life for patients with these conditions.
  • Are there any side effects associated with ofatumumab treatment? Like all medications, ofatumumab can have side effects. Common side effects may include infusion-related reactions, infections, and changes in blood cell counts. The specific side effects and their frequency can vary depending on the condition being treated and the individual patient.

Ongoing Clinical Trials on Ofatumumab

  • Study on the Effectiveness of Autologous Stem Cell Transplantation with Cytarabine in Patients with Aggressive Multiple Sclerosis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of Lactobacillales and Lacidofil in Multiple Sclerosis Patients: Comparing Effectiveness of Probiotic Therapy

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study on Anti-CD20 Therapy and Drug Combination for Patients with Relapsing-Remitting Multiple Sclerosis

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of KYV-101 Therapy for Patients with Refractory Primary and Secondary Progressive Multiple Sclerosis

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Germany Italy

  • Study on Ofatumumab Levels in Breast Milk of Women with Relapsing Multiple Sclerosis

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Poland

  • Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +15

  • Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study on Ofatumumab for Patients with Relapsing Multiple Sclerosis Transitioning from Fumarate-Based Therapies or Fingolimod

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Germany Latvia Poland Portugal Slovakia +2

  • Study on the Effectiveness and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Children with Multiple Sclerosis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Croatia Estonia France Germany +7

  • Study on Metformin for Delaying Progression in Non-Active Progressive Multiple Sclerosis Patients

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Monoclonal antibodies are used to treat some types of cancer and other diseases.
  • CD20: A protein found on the surface of B cells, which are a type of white blood cell. CD20 is targeted by certain medications, including ofatumumab, to help destroy B cells in various conditions.
  • Chronic lymphocytic leukemia (CLL): A type of cancer that affects the blood and bone marrow, causing an overproduction of abnormal white blood cells called lymphocytes.
  • Multiple sclerosis (MS): A chronic disease of the central nervous system that disrupts communication between the brain and other parts of the body, often leading to physical and cognitive impairments.
  • Neuromyelitis optica spectrum disorder (NMOSD): A rare autoimmune disease that affects the optic nerves and spinal cord, causing inflammation and damage to these areas.
  • Follicular lymphoma: A type of non-Hodgkin lymphoma that begins in the lymphatic system and is characterized by the presence of abnormal B cells.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time.
  • Annualized relapse rate (ARR): A measure used in clinical trials to assess the frequency of relapses in conditions like multiple sclerosis, calculated as the number of relapses per year.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.

References

  1. https://clinicaltrials.gov/study/NCT01613300
  2. https://clinicaltrials.gov/study/NCT00394836
  3. https://clinicaltrials.gov/study/NCT01453062
  4. https://clinicaltrials.gov/study/NCT01014208
  5. https://clinicaltrials.gov/study/NCT05504694
  6. https://clinicaltrials.gov/study/NCT01131247
  7. https://clinicaltrials.gov/study/NCT02388048